CheckMate 017 (nivolumab for squamous NSCLC) [25], CheckMate 057 (nivolumab for non-squamous NSCLC) [26], and OAK (atezolizumab for NSCLC) [27] enrolled patients regardless of PD-L1 expression status. This evidence concerns the gene CD274 and non-small cell lung carcinoma.